ARQT

Arcutis Biotherapeutics Inc

Sep 18 • 04:00PM ET

17.71

+0.57 3.33 %

Healthcare • Biotechnology • USA • NASD

Peers: BMRN ANAB RCUS BCRX TVRD CNTA DERM VERU SLNO KZIA

| Held by: VTI IWM XBI VXF IWO IBB SCHA VTWO VHT PINK

Index	RUT	P/E	-	EPS (ttm)	-0.74	Insider Own	12.67%	Shs Outstand	119.80M	Perf Week	0.11%
Market Cap	2.12B	Forward P/E	101.20	EPS next Y	0.17	Insider Trans	-1.19%	Shs Float	104.71M	Perf Month	12.30%
Enterprise Value	2.04B	PEG	-	EPS next Q	-0.09	Inst Own	98.63%	Short Float	16.25%	Perf Quarter	29.55%
Income	-93.27M	P/S	8.06	EPS this Y	60.34%	Inst Trans	0.70%	Short Ratio	9.80	Perf Half Y	6.69%
Sales	263.46M	P/B	15.27	EPS next Y	138.04%	ROA	-23.40%	Short Interest	17.02M	Perf YTD	27.14%
Book/sh	1.16	P/C	11.11	EPS next 5Y	-	ROE	-57.33%	52W High	18.15 -2.42%	Perf Year	74.31%
Cash/sh	1.59	P/FCF	-	EPS past 3/5Y	34.80% -0.98%	ROIC	-37.59%	52W Low	8.03 120.55%	Perf 3Y	-13.36%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	89.10%	Volatility	3.59% 3.98%	Perf 5Y	-24.45%
Dividend TTM	-	EV/Sales	7.75	EPS Y/Y TTM	65.91%	Oper. Margin	-32.58%	ATR (14)	0.72	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.04	Sales Y/Y TTM	99.50%	Profit Margin	-35.40%	RSI (14)	63.97	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	3.20	EPS Q/Q	70.48%	SMA20	6.97%	Beta	2.04	Target Price	22.75
Payout	-	Debt/Eq	0.79	Sales Q/Q	164.13%	SMA50	12.77%	Rel Volume	0.78	Prev Close	17.14
Employees	342	LT Debt/Eq	0.79	Earnings	Aug 06 AMC	SMA200	23.03%	Avg Volume	1.74M	Price	17.71
IPO	Jan 31, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	10.59% 10.61%	Trades		Volume	1,354,184	Change	3.33%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-25-25	Initiated	Goldman	Neutral	$18
Dec-30-24	Initiated	H.C. Wainwright	Buy	$19
Aug-28-24	Initiated	Jefferies	Buy	$15
Jan-03-24	Upgrade	Mizuho	Neutral → Buy	$4 → $8
Oct-26-23	Downgrade	Mizuho	Buy → Neutral	$57 → $4
Oct-13-23	Downgrade	Goldman	Buy → Neutral	$32 → $6
Sep-07-22	Initiated	Needham	Buy	$46
Mar-17-22	Initiated	Goldman	Buy	$45
Jun-30-21	Initiated	Mizuho	Buy	$58
May-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$52
Nov-09-20	Upgrade	Goldman	Neutral → Buy	$34 → $36
Oct-08-20	Initiated	Truist	Buy	$38
Feb-25-20	Initiated	Guggenheim	Buy	$36
Feb-25-20	Initiated	Goldman	Neutral	$30
Feb-25-20	Initiated	Cowen	Outperform	$55
Feb-25-20	Initiated	Cantor Fitzgerald	Overweight	$50

Show Previous Ratings

Sep-17-25 04:00AM	Arcutis To Present Multiple New ZORYVE (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress (GlobeNewswire)
Sep-16-25 09:00AM	Allure Magazine Honors Arcutis' ZORYVE (roflumilast) with Prestigious Best of Beauty Breakthrough Award (GlobeNewswire)
Sep-12-25 09:40AM	Are Medical Stocks Lagging AxoGen (AXGN) This Year? (Zacks)
Sep-11-25 11:17AM	Arcutis Biotherapeutics, Inc. (ARQT) Eyes Pediatric Expansion for ZORYVE Cream (Insider Monkey)
Sep-10-25 12:20AM	Arcutis Biotherapeutics Submits Supplemental New Drug Application to FDA For ZORYVE (Insider Monkey)
04:00PM	Loading…
Sep-05-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.80%
Sep-03-25 11:43AM	Arcutis Submits Supplemental New Drug Application for ZORYVE (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5 (GlobeNewswire)
Sep-01-25 09:55AM	Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 45.81% as Wall Street Analysts Expect? (Zacks)
Aug-27-25 09:40AM	Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-25-25 06:33PM	3 Biotech Catalysts Present Major Opportunity (MarketBeat)
Aug-19-25 04:00PM	Arcutis to Present at Upcoming Investor Conferences (GlobeNewswire) -5.79%
Aug-15-25 10:06AM	This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine (Investor's Business Daily) +5.69%
Aug-14-25 09:55AM	Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics (ARQT): Here's What You Should Know (Zacks)
Aug-11-25 09:40AM	Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year? (Zacks)
Aug-08-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
05:10PM	Loading…
Aug-06-25 05:10PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -8.07%
04:00PM	Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-25 09:49AM	Arcutis Biotherapeutics Inc (ARQT) Q2 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com) +5.54%
Jul-30-25 10:00AM	Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-23-25 04:00PM	Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 (GlobeNewswire)
Jul-17-25 12:28PM	Arcutis Stock Awaits Next Move In A Base; Its Skin Drug Sales Grew 196% (Investor's Business Daily)
Jul-10-25 02:26PM	Arcutis Biotherapeutics Stock Scores RS Rating Upgrade (Investor's Business Daily) +7.38%
Jul-09-25 12:55AM	Arcutis' ZORYVE Receives AAD Recommendation for Adult Atopic Dermatitis (Insider Monkey)
Jul-03-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-26-25 08:00AM	Arcutis' ZORYVE (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis (GlobeNewswire)
Jun-15-25 05:43AM	Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials (Insider Monkey)
Jun-11-25 07:03AM	First child enrolled in Arcutis Phase II trial of cream for atopic dermatitis (Clinical Trials Arena)
Jun-10-25 08:00AM	Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis (GlobeNewswire)
Jun-06-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.37%
08:00AM	Arcutis to Present New Long-Term Results of ZORYVE (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference (GlobeNewswire)
04:00PM	Loading…
May-29-25 04:00PM	Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-22-25 02:12PM	Arcutis' ZORYVE (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older (GlobeNewswire)
May-15-25 09:29AM	New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice (GlobeNewswire)
May-08-25 11:26AM	Arcutis Biotherapeutics: Zoryve foam treatment resulted in major improvements (TipRanks)
May-07-25 11:47AM	Q1 2025 Arcutis Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
11:18AM	Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology (GlobeNewswire)
03:21AM	Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
May-06-25 11:00PM	Arcutis Biotherapeutics, Inc. (ARQT) Q1 2025 Earnings Call Transcript (Seeking Alpha) -7.07%
05:10PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:00PM	Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-05-25 09:43AM	What To Expect From Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings (GuruFocus.com)
May-02-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-01-25 08:15AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-30-25 10:01AM	Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Apr-29-25 10:01AM	Arcutis Biotherapeutics, Inc. (ARQT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-24-25 09:40AM	Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Apr-19-25 01:41AM	Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets (Seeking Alpha)
Apr-17-25 08:00AM	Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025 (GlobeNewswire)
Apr-10-25 04:30PM	Arcutis Announces Chief Financial Officer Transition (GlobeNewswire) -7.76% -6.32%
Apr-04-25 11:10PM	Arcutis Biotherapeutics: Zoryve's Growth Impresses, But Valuation Is A Concern (Rating Upgrade) (Seeking Alpha) -8.85%
04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-03-25 10:01AM	Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last? (Zacks)
04:47AM	Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday? (Insider Monkey)
Apr-02-25 01:16PM	Arcutis and Padagis Agree to Stay Patent Lawsuit (GlobeNewswire) +10.81%
Mar-28-25 04:15PM	Why IBD 50's Arcutis Is Outplaying The Biotech Tape And Just Reentered Its Buy Zone (Investor's Business Daily)
09:55AM	How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85% (Zacks)
09:40AM	Are Medical Stocks Lagging Cardinal Health (CAH) This Year? (Zacks)
Mar-27-25 08:00AM	Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-17-25 07:00AM	ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age (PR Newswire) +12.31%
Mar-12-25 09:40AM	Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year? (Zacks)
Mar-07-25 08:00AM	Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting (GlobeNewswire)
Mar-06-25 09:30AM	Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average (Zacks)
Mar-05-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.30%
09:55AM	Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? (Zacks)
Feb-28-25 09:00AM	Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting (GlobeNewswire) +6.95%
Feb-26-25 08:00AM	U.S. FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis (GlobeNewswire) +8.36%
02:15AM	Arcutis Biotherapeutics Inc (ARQT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Feb-25-25 05:10PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:00PM	Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
01:33AM	Arcutis Biotherapeutics Inc (ARQT) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-24-25 08:00AM	Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology (GlobeNewswire)
Feb-18-25 04:35PM	Arcutis to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-17-25 09:55AM	Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 51.64%: Read This Before Placing a Bet (Zacks)
Feb-13-25 10:18AM	Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains? (Zacks) -6.81%
Feb-11-25 09:55AM	Here's Why Arcutis Biotherapeutics (ARQT) Could be Great Choice for a Bottom Fisher (Zacks)
Feb-06-25 08:00AM	Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains. (Investor's Business Daily) -5.77%
Feb-05-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-04-25 09:15AM	Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a 'Clear Win for Your Skin' (PR Newswire)
Jan-27-25 08:00AM	Arcutis to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-16-25 09:55AM	Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 37.43%: Here's is How to Trade (Zacks)
Jan-12-25 08:30AM	Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million (GlobeNewswire)
Jan-06-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.14%
Dec-16-24 08:00AM	Arcutis Submits ZORYVE (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis (GlobeNewswire) +6.93%
Dec-06-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-03-24 08:00AM	Arcutis Announces Promotions on Executive Management Team (GlobeNewswire)
Nov-27-24 09:55AM	Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 60.12% as Wall Street Analysts Expect? (Zacks)
09:55AM	Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Nov-20-24 09:30AM	Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average (Zacks)
09:30AM	Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks)
Nov-19-24 09:55AM	Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now (Zacks) +7.00%
09:35AM	Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average (Zacks)
Nov-13-24 08:00AM	Arcutis' ZORYVE (roflumilast) Awarded Best Eczema Treatment by Glamour (GlobeNewswire)
Nov-11-24 09:55AM	Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? (Zacks)
Nov-07-24 02:23AM	Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ... (GuruFocus.com) +7.66%
Nov-06-24 05:15PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:00PM	Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-24 07:52AM	Earnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2024 Result (GuruFocus.com) +6.65%
Nov-04-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-25-24 10:00AM	Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-24-24 08:00AM	Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting (GlobeNewswire)

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Watanabe Todd	See Remarks	Sep 08 '25	Sale	17.54	9,625	168,799	891,944	Sep 10 06:21 PM
Watanabe Todd	See Remarks	Sep 09 '25	Sale	17.52	504	8,829	891,440	Sep 10 06:21 PM
Watanabe Todd	Officer	Sep 09 '25	Proposed Sale	17.52	504	8,829		Sep 09 03:17 PM
Matsuda Masaru	See Remarks	Sep 04 '25	Sale	16.16	36,130	583,716	161,234	Sep 08 05:14 PM
Watanabe Todd	Officer	Sep 08 '25	Proposed Sale	17.54	9,625	168,800		Sep 08 05:04 PM
Welgus Howard G.	Director	Sep 02 '25	Option Exercise	0.00	10,000	0	110,206	Sep 04 06:41 PM
Welgus Howard G.	Director	Sep 02 '25	Sale	15.64	10,000	156,383	100,206	Sep 04 06:41 PM
Matsuda Masaru	Officer	Sep 04 '25	Proposed Sale	16.16	36,130	583,716		Sep 04 04:21 PM
Welgus Howard G.	Director	Sep 02 '25	Proposed Sale	15.61	10,000	156,083		Sep 02 03:08 PM
Burnett Patrick	See Remarks	Aug 21 '25	Sale	15.57	2,438	37,969	104,811	Aug 21 09:32 PM
Burnett Patrick	See Remarks	Aug 19 '25	Sale	16.16	1,750	28,281	107,249	Aug 21 09:32 PM
Burnett Patrick	Officer	Aug 21 '25	Proposed Sale	15.57	2,438	37,969		Aug 21 05:27 PM
Burnett Patrick	Officer	Aug 19 '25	Proposed Sale	16.13	1,750	28,228		Aug 19 04:57 PM
Burnett Patrick	See Remarks	Aug 08 '25	Sale	14.03	3,847	53,988	108,999	Aug 12 05:04 PM
Topper David Joseph	Former Officer	Aug 08 '25	Proposed Sale	14.58	41,979	611,936		Aug 08 04:40 PM
Burnett Patrick	Officer	Aug 08 '25	Proposed Sale	14.03	3,847	53,989		Aug 08 04:10 PM
Topper David Joseph	Former Officer	Aug 06 '25	Proposed Sale	14.99	53,187	797,446		Aug 06 03:04 PM
Watanabe Todd	See Remarks	Aug 04 '25	Sale	14.33	11,547	165,429	901,569	Aug 05 06:29 PM
Burnett Patrick	See Remarks	Aug 04 '25	Sale	14.33	2,622	37,564	112,846	Aug 05 06:28 PM
Vairavan Latha	SVP Chief Financial Officer	Aug 04 '25	Sale	14.33	89	1,275	65,015	Aug 05 06:28 PM
Matsuda Masaru	See Remarks	Aug 04 '25	Sale	14.33	6,330	90,687	197,364	Aug 05 06:28 PM
Welgus Howard G.	Director	Aug 01 '25	Option Exercise	0.00	10,000	0	106,316	Aug 05 06:28 PM
Welgus Howard G.	Director	Aug 01 '25	Sale	14.30	10,000	142,982	100,206	Aug 05 06:28 PM
Watanabe Todd	Officer	Aug 04 '25	Proposed Sale	14.33	11,547	165,429		Aug 04 03:43 PM
Burnett Patrick	Officer	Aug 04 '25	Proposed Sale	14.33	2,622	37,564		Aug 04 03:42 PM
Matsuda Masaru	Officer	Aug 04 '25	Proposed Sale	14.33	6,330	90,687		Aug 04 03:40 PM
Vairavan Latha	Officer	Aug 04 '25	Proposed Sale	14.10	89	1,255		Aug 04 03:38 PM
Welgus Howard G.	Director	Aug 01 '25	Proposed Sale	14.30	10,000	142,982		Aug 01 04:20 PM
Burnett Patrick	See Remarks	Jul 10 '25	Option Exercise	0.00	23,000	0	138,468	Jul 14 04:02 PM
Burnett Patrick	See Remarks	Jul 14 '25	Option Exercise	0.00	5,750	0	121,218	Jul 14 04:02 PM
Burnett Patrick	See Remarks	Jul 10 '25	Sale	15.05	23,000	346,046	115,468	Jul 14 04:02 PM
Burnett Patrick	See Remarks	Jul 14 '25	Sale	15.07	5,750	86,654	115,468	Jul 14 04:02 PM
Burnett Patrick	Officer	Jul 14 '25	Proposed Sale	15.07	5,750	86,654		Jul 14 12:27 PM
Burnett Patrick	Officer	Jul 10 '25	Proposed Sale	15.05	23,000	346,047		Jul 10 03:55 PM
Welgus Howard G.	Director	Jul 01 '25	Sale	13.84	9,208	127,430	100,206	Jul 02 04:25 PM
Welgus Howard G.	Director	Jul 01 '25	Proposed Sale	13.84	9,208	127,431		Jul 01 10:12 AM
Welgus Howard G.	Director	Jun 18 '25	Sale	13.37	10,139	135,574	109,414	Jun 20 04:32 PM
Welgus Howard G.	Director	Jun 18 '25	Proposed Sale	13.37	10,139	135,573		Jun 18 02:09 PM
Heron Patrick J	Director	Jun 13 '25	Buy	13.08	2,646	34,610	27,448	Jun 17 05:45 PM
Heron Patrick J	Director	Jun 04 '25	Buy	13.32	1,890	25,177	24,424	Jun 06 08:44 AM
Heron Patrick J	Director	Jun 05 '25	Buy	13.41	378	5,069	24,802	Jun 06 08:44 AM
Matsuda Masaru	See Remarks	May 28 '25	Sale	13.78	1,800	24,807	202,599	May 29 08:25 PM
Matsuda Masaru	Officer	May 28 '25	Proposed Sale	13.78	1,800	24,807		May 28 03:47 PM
Heron Patrick J	Director	May 21 '25	Buy	13.66	2,520	34,423	20,014	May 23 04:04 PM
Heron Patrick J	Director	May 22 '25	Buy	13.65	2,520	34,398	22,534	May 23 04:04 PM
Edwards Larry Todd	See Remarks	May 19 '25	Sale	14.07	7,451	104,850	183,104	May 20 04:37 PM
Heron Patrick J	Director	May 15 '25	Buy	13.62	2,520	34,317	17,494	May 19 04:14 PM
Edwards Larry Todd	Officer	May 19 '25	Proposed Sale	14.07	7,451	104,850		May 19 03:54 PM
Heron Patrick J	Director	May 14 '25	Buy	13.76	6,300	86,691	14,974	May 15 04:18 PM
Heron Patrick J	Director	May 13 '25	Buy	13.76	2,374	32,661	8,674	May 15 04:18 PM
Heron Patrick J	Director	May 09 '25	Buy	13.60	6,300	85,691	6,300	May 13 04:11 PM
Burnett Patrick	See Remarks	May 08 '25	Sale	13.59	3,871	52,623	115,468	May 09 07:45 PM
Burnett Patrick	Officer	May 08 '25	Proposed Sale	13.59	3,871	52,623		May 08 02:54 PM
Matsuda Masaru	See Remarks	May 02 '25	Sale	15.20	5,030	76,453	204,399	May 05 05:20 PM
Watanabe Todd Franklin	See Remarks	May 02 '25	Sale	15.19	11,448	173,917	913,795	May 05 05:20 PM
Burnett Patrick	See Remarks	May 02 '25	Sale	15.19	2,597	39,442	119,339	May 05 05:20 PM
Welgus Howard G.	Director	May 01 '25	Sale	14.64	10,000	146,357	111,944	May 05 04:49 PM
Watanabe Todd Franklin	Officer	May 02 '25	Proposed Sale	15.19	11,448	173,917		May 02 04:24 PM
Burnett Patrick	Officer	May 02 '25	Proposed Sale	15.19	2,597	39,442		May 02 04:20 PM
Matsuda Masaru	Officer	May 02 '25	Proposed Sale	15.20	5,030	76,454		May 02 04:20 PM
Welgus Howard G.	Director	May 01 '25	Proposed Sale	14.64	10,000	146,357		May 01 04:21 PM
Welgus Howard G.	Director	Apr 01 '25	Sale	15.12	10,000	151,236	121,944	Apr 03 04:21 PM
Topper David Joseph	Chief Financial Officer	Apr 02 '25	Sale	15.80	9,600	151,698	182,774	Apr 03 04:21 PM
Topper David Joseph	Officer	Apr 02 '25	Proposed Sale	15.80	9,600	151,698		Apr 02 04:18 PM
Welgus Howard G.	Director	Apr 01 '25	Proposed Sale	15.12	10,000	151,236		Apr 01 04:07 PM
Watanabe Todd Franklin	See Remarks	Mar 25 '25	Sale	17.56	2,171	38,131	925,243	Mar 26 04:41 PM
Watanabe Todd Franklin	See Remarks	Mar 24 '25	Sale	17.52	1,500	26,282	927,414	Mar 26 04:41 PM
Watanabe Todd Franklin	Officer	Mar 25 '25	Proposed Sale	17.56	2,171	38,131		Mar 25 05:09 PM
Watanabe Todd Franklin	Officer	Mar 24 '25	Proposed Sale	17.52	1,500	26,282		Mar 24 04:20 PM
Watanabe Todd Franklin	See Remarks	Mar 17 '25	Sale	17.61	1,200	21,137	928,914	Mar 20 06:27 PM
Watanabe Todd Franklin	Officer	Mar 17 '25	Proposed Sale	17.61	1,200	21,137		Mar 20 05:03 PM
Burnett Patrick	See Remarks	Mar 13 '25	Option Exercise	0.00	5,008	0	126,944	Mar 17 04:51 PM
Burnett Patrick	See Remarks	Mar 14 '25	Option Exercise	0.00	12,242	0	134,178	Mar 17 04:51 PM
Burnett Patrick	See Remarks	Mar 13 '25	Sale	14.98	49,161	736,403	121,936	Mar 17 04:51 PM
Burnett Patrick	See Remarks	Mar 14 '25	Sale	15.04	12,242	184,107	121,936	Mar 17 04:51 PM
Burnett Patrick	Officer	Mar 04 '25	Proposed Sale	15.04	12,242	184,107		Mar 14 04:19 PM
Burnett Patrick	Officer	Mar 04 '25	Proposed Sale	14.98	49,161	736,403		Mar 13 05:10 PM
Burnett Patrick	See Remarks	Mar 03 '25	Sale	13.03	2,819	36,735	167,043	Mar 04 07:44 PM
Burnett Patrick	See Remarks	Mar 04 '25	Sale	13.28	954	12,673	166,089	Mar 04 07:44 PM
Watanabe Todd Franklin	See Remarks	Mar 03 '25	Sale	13.03	20,880	272,089	934,249	Mar 04 07:43 PM
Watanabe Todd Franklin	See Remarks	Mar 04 '25	Sale	13.28	4,135	54,930	930,114	Mar 04 07:43 PM
Welgus Howard G.	Director	Mar 03 '25	Sale	13.00	10,000	130,048	131,944	Mar 04 07:43 PM
Matsuda Masaru	See Remarks	Mar 03 '25	Sale	13.03	3,263	42,520	209,429	Mar 04 07:43 PM
Burnett Patrick	Officer	Mar 04 '25	Proposed Sale	13.28	954	12,673		Mar 04 04:47 PM
Watanabe Todd Franklin	Officer	Mar 04 '25	Proposed Sale	13.28	4,135	54,929		Mar 04 04:46 PM
Watanabe Todd Franklin	Officer	Mar 03 '25	Proposed Sale	13.03	20,880	272,089		Mar 03 05:39 PM
Matsuda Masaru	Officer	Mar 03 '25	Proposed Sale	13.03	3,263	42,520		Mar 03 05:38 PM
Burnett Patrick	Officer	Mar 03 '25	Proposed Sale	13.03	2,819	36,735		Mar 03 05:36 PM
Welgus Howard G.	Director	Mar 03 '25	Proposed Sale	13.00	10,000	130,048		Mar 03 04:50 PM
Matsuda Masaru	See Remarks	Feb 03 '25	Sale	12.70	8,338	105,893	178,692	Feb 04 08:01 PM
Watanabe Todd Franklin	See Remarks	Feb 03 '25	Sale	12.70	19,301	245,123	804,129	Feb 04 08:01 PM
Welgus Howard G.	Director	Feb 03 '25	Sale	12.71	10,000	127,100	141,944	Feb 04 08:00 PM
Burnett Patrick	See Remarks	Feb 03 '25	Sale	12.70	12,116	153,873	114,862	Feb 04 08:00 PM
Edwards Larry Todd	See Remarks	Feb 03 '25	Sale	12.70	2,173	27,597	135,555	Feb 04 08:00 PM
Watanabe Todd Franklin	Officer	Feb 03 '25	Proposed Sale	12.70	19,301	245,098		Feb 03 06:04 PM
Matsuda Masaru	Officer	Feb 03 '25	Proposed Sale	28.98	8,338	241,670		Feb 03 06:03 PM
Edwards Larry Todd	Officer	Feb 03 '25	Proposed Sale	12.70	2,173	27,595		Feb 03 06:02 PM
Burnett Patrick	Officer	Feb 03 '25	Proposed Sale	12.70	12,116	153,858		Feb 03 06:01 PM
Welgus Howard G.	Director	Feb 03 '25	Proposed Sale	12.71	10,000	127,091		Feb 03 05:10 PM
Welgus Howard G.	Director	Jan 02 '25	Sale	14.67	10,000	146,714	151,944	Jan 06 04:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARQT

Arcutis Biotherapeutics Inc

Upgrade your FINVIZ experience